- Trials with a EudraCT protocol (942)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
942 result(s) found for: Drug Resistance.
Displaying page 1 of 48.
EudraCT Number: 2020-004084-10 | Sponsor Protocol Number: T001018N | Start Date*: 2022-05-16 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Flemisch Fund for Scientific Research - Fonds voor Wetenschappelijk Onderzoek | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment; a pragmatic randomised controlled trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Rifampicin resistant (RR-TB) and drug resistant (DR-TB) tuberculosis | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001003-38 | Sponsor Protocol Number: RGHT000540 | Start Date*: 2008-08-01 | |||||||||||
Sponsor Name:The Royal Group of Hospitals, Belfast Trust | |||||||||||||
Full Title: A study investigating rimonabant versus placebo in conjunction with a strict low-fat weight reduction diet in overweight and obese subjects: effects on glucose and lipid metabolism and cardiovascul... | |||||||||||||
Medical condition: This study will investigate subjects who are overweight and obese with Body Mass Index >27kg/m2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001232-42 | Sponsor Protocol Number: RGHT000270 | Start Date*: 2006-06-14 |
Sponsor Name:Royal Group of Hospitals Trust | ||
Full Title: The Pharmacogenetics of Aspirin Resistance | ||
Medical condition: Aspirin resistance: Vascular diseases are common problems and aspirin is used as an anti-platelet drug to prevent thrombosis. However, aspirin's anti-platelet effect may not be uniform in all patie... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-009278-29 | Sponsor Protocol Number: S51477 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:UZ Leuven | ||||||||||||||||||||||||||||
Full Title: Follow-up studie: Metformin therapie bij kinderen en adolescenten met neurogene of neuromusculaire aandoeningen | ||||||||||||||||||||||||||||
Medical condition: Neuromuscular and neurological diseases, associated with obesity and insulin resistance | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020875-22 | Sponsor Protocol Number: MetSNS | Start Date*: 2010-08-20 | |||||||||||||||||||||
Sponsor Name:RUNMC | |||||||||||||||||||||||
Full Title: In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS). Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resista... | |||||||||||||||||||||||
Medical condition: Subjects suffer from the metabolic syndrome. Effects of study medication on insulin resistance and vascular function will be studied respectively. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-007748-33 | Sponsor Protocol Number: AIRCo01.12.2008/1 | Start Date*: 2010-04-09 | |||||||||||
Sponsor Name:Foreest Medical School | |||||||||||||
Full Title: Dipeptide Alanyl Glutamine Prevents Postoperative Insulin Resistance in Colon Carcinoma Patients | |||||||||||||
Medical condition: Insulin resistance in colon cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000935-18 | Sponsor Protocol Number: UoL000841 | Start Date*: 2012-06-28 | |||||||||||
Sponsor Name:University of Liverpool [...] | |||||||||||||
Full Title: TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Ind... | |||||||||||||
Medical condition: Insulin resistance in HIV-positive patients treated with antiretroviral therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000197-35 | Sponsor Protocol Number: IR-HP-14-01 | Start Date*: 2015-06-09 | ||||||||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | ||||||||||||||||||
Full Title: insulin resistance, obesity and gastrointestinal bacteria | ||||||||||||||||||
Medical condition: Helicobacter pylori infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001562-16 | Sponsor Protocol Number: RGHT000278 | Start Date*: 2006-11-01 | |||||||||||
Sponsor Name:Royal Group of Hospitals Trust | |||||||||||||
Full Title: Studies of insulin action in patients at increased vascular risk. Modulation by antihypertensive and endocrine replacement therapy. | |||||||||||||
Medical condition: Protocol (a): Essential Hypertension Protocol (b): Hypertension in Type 2 Diabetes Protocol (c): Panhypopituitarism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002368-27 | Sponsor Protocol Number: VIT C | Start Date*: 2005-07-01 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: EFFECT OF AN ANTI-OXIDANT TREATMENT ON RESISTIN SERUM LEVELS. A RANDOMISED STUDY | |||||||||||||
Medical condition: Data suggesting participation of resistin, a new discovered protein, whose biological significance is still uncertain, in oxidative processes have been sporadically published. One is tempted to spe... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002633-39 | Sponsor Protocol Number: SHCS-Projekt Nr. 408 | Start Date*: 2005-02-17 |
Sponsor Name:Prof. Dr. med. Milos Opravil, Universitätsspital Zürich | ||
Full Title: Prospective study of switch to 3TC monotherapy with evaluation of replication capacity in patients with virologic failure and 3TC resistance (a multicenter prospective clinical study within the SH... | ||
Medical condition: HIV patients with virological treatment failure due to multi-drug-resistant virus including 3TC resistance | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000290-84 | Sponsor Protocol Number: GESIDA11820 | Start Date*: 2021-04-26 |
Sponsor Name:Seimc-Gesida Foundation | ||
Full Title: Virologic Outcomes of Lamivudine/Dolutegravir in Virologically suppressed subjects with Expected or confirmed Resistance to Lamivudine (VOLVER study). | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012876-29 | Sponsor Protocol Number: 10762 | Start Date*: 2009-07-07 |
Sponsor Name:University Hospitals Leicester | ||
Full Title: A prospective study to assess emergence and transmissibility of drug resistance to neuraminidase inhibitor following treatment of children and adults with acute pandemic influenza | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010999-19 | Sponsor Protocol Number: MEC-2009-074 | Start Date*: 2010-07-07 | |||||||||||
Sponsor Name:Erasmus MC - Sophia Children's Hospital | |||||||||||||
Full Title: Protein and Energy Interactions in Critically Ill Children | |||||||||||||
Medical condition: We want to study protein, glucose and lipid metabolism in critically ill septic children admitted to the PICU. As these children often receive insulin because of hyperglycemia due to insulin resist... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001953-24 | Sponsor Protocol Number: WON001 | Start Date*: 2007-07-21 |
Sponsor Name:University of Dundee | ||
Full Title: ''Metformin in Insulin Resistant LV Dysfunction, a double-blind, placebo-controlled trial'' | ||
Medical condition: Patients who has heart failure and found to be insulin resistant (pre-diabetic state). Insulin resistance can be identified using a blood test. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002601-69 | Sponsor Protocol Number: CA180-013 | Start Date*: 2005-01-25 |
Sponsor Name:Bristol Myers Squibb International Corporation | ||
Full Title: A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Ima... | ||
Medical condition: Chronic phase Philadelphia chromosome-positive chronic myeloid leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) SE (Completed) FI (Completed) GB (Completed) IE (Completed) IT (Completed) BE (Completed) ES (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017176-25 | Sponsor Protocol Number: WMLREC and BBC LREC | Start Date*: 2010-09-08 |
Sponsor Name:Sandwell and West Birmingham NHS Trust | ||
Full Title: Aspirin resistance and heart disease | ||
Medical condition: Index group 1 : coronary artery disease Index group 2: atrial fibrillation Control group 1: Diabetes/hypertension/hypercholesterolaemia Control group 2: Healthy subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005239-80 | Sponsor Protocol Number: 10007 | Start Date*: 2005-12-23 |
Sponsor Name:University Hospitals Leicester, Leicester General Hospital | ||
Full Title: Prospective study to assess the emergence of drug resistance to oseltamivir following treatment of acute influenza A among children | ||
Medical condition: Influenza A | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000588-26 | Sponsor Protocol Number: MK-8591A-019 | Start Date*: 2020-03-02 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doraviri... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000942-11 | Sponsor Protocol Number: 140207 | Start Date*: 2008-04-30 |
Sponsor Name:Medizinische Universität Wien/ Universitätsklinik für Innere Medizin II/ Angiologie und Kardiologie | ||
Full Title: Vienna-Resistance to Antithrombotic Therapy (REACT) | ||
Medical condition: Resistance to Aspirin and Clopidogrel | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.